Summary
Impact on safety and cost of pharmaceutical interventions in the emergency department (INTERPHAR): a standardized methodology for multicenter documentation
Javier Ramos-Rodríguez1,2, Manuel Bonete-Sánchez1,3, Jesús Ruíz-Ramos1,4, Beatriz Calderón-Hernanz1,5, Ainara Campino-Villegas1,6, Ana de Lorenzo-Pinto1,7, Milagros García-Peláez1,8, María del Mar García-Gutiérrez1,9, Ángeles García-Martín1,10, José Manuel Real-Campaña1,11, Ana Ginés-Palomares1,12, Ana Such-Díaz1,13, Emili Vallvé-Alcón1,14, Héctor Alonso-Ramos1,15, en representación del Grupo de trabajo de Atención Farmacéutica en Urgencias de la SEFH (REDFASTER)
Affiliation of the authors
1Grupo de trabajo de Atención Farmacéutica en Urgencias de la SEFH (REDFASTER). 2Corporació Sanitaria Parc Tauli, Sabadell, Barcelona, Spain. 3Hospital Universitario San Juan de Alicante, Spain. 4Hospital Santa Creu i Sant Pau, Barcelona, Spain. 5Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain. 6Hospital Universitario de Cruces, Bilbao, Spain. 7Hospital General Universitario Gregorio Marañón, Madrid, Spain. 8Hospital Asepeyo, Sant Cugat, Barcelona, Spain. 9Hospital de Fuenlabrada, Madrid, Spain. 10Hospital Universitario La Paz, Madrid, Spain. 11Hospital Universitario Miguel Servet, Zaragoza, Spain. 12Hospital Universitario Príncipe de Asturias, Madrid, Spain. 13Hospital Universitario Infanta Leonor, Madrid, Spain. 14Hospital Universitari Vall d’Hebron, Barcelona, Spain. 15Hospital Universitario Dr.Negrín, Las Palmas de Gran Canaria, Spain.
DOI
Quote
Ramos-Rodríguez J, Bonete-Sánchez M, Ruíz-Ramos J, Calderón-Hernanz B, Campino-Villegas A, de Lorenzo-Pinto A, et al. Impact on safety and cost of pharmaceutical interventions in the emergency department (INTERPHAR): a standardized methodology for multicenter documentation. Emergencias. 2025;37:367-72
Summary
Objectives.
Methods.
Results.
individualized care, 22.4% (1,269) to adverse event prevention, 2.4% (135) to direct patient care, and 1.3% (75) to resource
optimization; 1.5% (85) were not classifiable. Overall, 94.5% of PIs had a level of evidence III, 4.2% level IV, 1.2% level Ib, and 0.1% level IIa. The potential cost avoided amounted to €1,984,474.90.
Conclusions.
